Metformin and weight changes in non-diabetic older people with HIV (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial

Clicks: 24
ID: 324428
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #158 of 326 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 326 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Weight gain is a major complication of contemporary antiretroviral treatment (ART). We evaluated the effects of metformin on weight trajectories and metabolic outcomes in non-diabetic, non-obese, older persons with HIV (PWH). Methods In this double-blind, randomised, placebo-controlled pilot trial (METFORAGING), PWH 50 years or older, virologically suppressed, without diabetes or insulin resistance, were randomly assigned (1:1) to metformin 850 mg or placebo twice daily for 96 weeks at La Paz University Hospital (Madrid, Spain). This prespecified secondary analysis evaluated changes in body weight, body mass index (BMI), glycaemic indices, lipid parameters, and serum growth differentiation factor-15 (GDF-15) in the per-protocol population. Results Forty participants were randomly assigned (metformin n=19; placebo n=21); 35 completed treatment through week 96 (per-protocol population). At week 96, mean weight change was −1.5 kg (95% CI −2.9 to −0.03) with metformin and +1.3 kg (−0.7 to 3.3) with placebo (between-group difference −2.8 kg [95% CI −5.2 to −0.4]; p=.025). After discontinuation, weight in the metformin group returned towards baseline (between-group difference from week 96 to 144: 2.2 kg [95% CI 0.05 to 4.5]; p=.045). At week 96, changes in body weight correlated inversely with changes in serum GDF-15 in the metformin group (r=−0.67; p=.003). No serious adverse events were attributed to metformin. Conclusions Metformin attenuated weight gain in non-diabetic, non-obese PWH receiving contemporary ART, but the effect was not sustained after discontinuation. These findings support larger trials to confirm efficacy and define optimal treatment duration. Trial Registration. EudraCT 2021-003299-15.
Reference Key
openalex_W7201841292 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cristina Marcelo, Andrés Esteban-Cantos, Francisco Jurado, Rocío Montejano, Lucía Gutiérrez-García, Alejandro de Gea-Grela, Patricia Martínez-Martín, Alejandro Vidal, Rosa de Miguel Buckley, Carlos M Oñoro-López, J González, Luz Martín‐Carbonero, José Ignacio Bernardino, Rocío Menéndez Colino, Noemí González Pérez de Villar, Berta Rodés, José Ramón Arribas
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag489
URL
https://doi.org/10.1093/ofid/ofag489
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.